Recursion Pharmaceuticals (RXRX) Cash from Operations Growth (3y) (2023 - 2026)

Recursion Pharmaceuticals (RXRX) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Recursion Pharmaceuticals 1.59 Bn 933.22 Mn -6.02 Mn -3.42%

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.42%
Dec 31, 2025 -0.98%
Sep 30, 2025 -29.10%
Jun 30, 2025 -7.44%
Mar 31, 2025 -54.74%
Dec 31, 2024 -23.58%
Sep 30, 2024 -21.47%
Jun 30, 2024 -34.68%
Mar 31, 2024 -49.27%
Dec 31, 2023 -119.95%
Sep 30, 2023 -55.33%
Jun 30, 2023 -59.27%
Mar 31, 2023 -60.25%